Corporate Advisory

PharmaTelevision

Industry Insight and Intelligence

 

Watch the Latest Videos

PharmaTelevision News Review boasts face-to-face interviews and panel discussions with key industry figures.

More
Image of woman with pen

Register for E-Mail Updates

Email Address
Submit

Keeping You Updated

PharmaVentures acts as advisor and broker to Dr Reddy’s to identify and secure product marketing opportunities for the Russian/CIS market.

Oxford, UK, 26th October, 2010: PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy’s Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy’s exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics’ leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.

The engagement with Dr Reddy’s utilised PharmaVentures' significant and established pharmaceutical transactions experience in the healthcare transactions sector. Dr Fintan Walton, Chief Executive, PharmaVentures said, “We are delighted to bring another successful outcome to one of our important international clients, Dr Reddy’s. We are proud to have acted as advisor and broker to one of India’s premier pharmaceutical companies, particularly in assisting them to achieve their business goals in the increasingly expanding Russian/CIS market”.

PharmaVentures acted as advisor and broker to the Dow Chemical Corporation in the sale of its small molecule pharmaceutical manufacturing business to Dr Reddy’s, under a separate agreement in 2008.

Over the past 18 years, PharmaVentures has acted as advisors to numerous pharmaceutical and biopharmaceutical clients in transactions covering the licensing, merger, acquisition, divestment and joint venture activities for companies located worldwide.

For press enquiries, please contact:

Dr Fintan Walton, CEO

PharmaVentures

enquiries@pharmaventures.com

+44 (0) 1865 332700

- ends -

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more www.pharmaventures.com

Our services include:

  • M&A (divestments, mergers, acquisitions and strategic transactions)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
  • Licensing (in and out licensing)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 21st year, PharmaVentures is based in Oxford, UK, and employs over 17 people.

For further information, contact:

Dr Fintan Walton
CEO
PharmaVentures Ltd
+44 1865 332700
enquiries@pharmaventures.com